Kenneth C. Anderson
Translated bortezomib and lenalidomide from bench to bedside, helping turn myeloma from a two-year to a decade-plus disease.
Myeloma pioneer whose laboratory and clinical work underpinned the approval of bortezomib, lenalidomide and later novel agents; long-time director of the Lipper Myeloma Center.
| Title | Journal | Year |
|---|---|---|
| Bortezomib or high-dose dexamethasone for relapsed multiple myeloma | New England Journal of Medicine | 2005 |
Pages like this
not linked directly; found by shared links- PersonPaul G. Richardson
Shares Bortezomib, Lenalidomide, Dana-Farber Brigham Cancer Center, Multiple myeloma.
- PersonBenjamin L. Ebert
Shares American Society of Hematology, Lenalidomide, Dana-Farber Brigham Cancer Center, Multiple myeloma.
- TrialCEPHEUS
Shares Bortezomib, Lenalidomide, Multiple myeloma.
- TrialIMROZ
Shares Bortezomib, Lenalidomide, Multiple myeloma.
- TrialDREAMM-7
Shares Bortezomib, Multiple myeloma.
- ProductIberdomide
Shares Lenalidomide, Multiple myeloma.
- TrialPERSEUS
Shares Bortezomib, Lenalidomide, Multiple myeloma.
- PersonSundar Jagannath
Shares Bortezomib, Multiple myeloma.